Longevity Papers 2025-01-16

In this episode of Longevity Papers, we analyze five standout papers from longevitypapers.com covering the past four weeks of longevity research (February-March 2026): 1) Microbiome depletion rejuvenates the aging brain (Gasperini, Holton, Limone et al., Harvard University, February 15, 2026, bioRxiv, https://www.biorxiv.org/content/10.64898/2026.02.13.705770v1 ) - Antibiotic-induced microbiome depletion in aged mice triggers widespread brain rejuvenation including improved neurogenesis, myelination, vascular density, and memory. The aged gut microbiome drives brain aging through eotaxin-1 (CCL11) - the same factor found elevated in old blood in the classic heterochronic parabiosis studies. Inhibiting eotaxin-1 alone was sufficient to reverse multiple brain aging hallmarks. 2) Transplanting ANXA1- CD8+ Naive T cells Delay Aging Through Senolysis (Wu, Guo, Zhang et al., Shanghai Jiao Tong University, February 23, 2026, bioRxiv, https://www.biorxiv.org/content/10.64898/2026.02.21.707223v1 ) - Monthly transfer of ANXA1-deficient CD8+ naive T cells into aged mice extended median lifespan by more than 30 weeks and improved cardiac function, bone density, and motor coordination. The aging immune system fails to clear senescent cells because CD8+ naive T cells accumulate an ANXA1+ senescent-like subpopulation. Removing this subpopulation restores immune senolysis. 3) Organism-wide cellular dynamics and epigenomic remodeling in mammalian aging (Lu, Zhang, Xu et al., Rockefeller University, February 26, 2026, Science, https://www.science.org/doi/10.1126/science.adw6273 ) - Landmark single-cell chromatin atlas of approximately 7 million cells across 21 mouse tissues at three ages reveals that 25% of cell types show dramatic age-related population shifts including loss of kidney podocytes, muscle tenocytes, and lung aerocytes. Critically, 40% of aging dynamics differ between males and females. 4) The glycolytic metabolite phosphoenolpyruvate restricts cGAS-driven inflammation to promote healthy aging (Song, Hu, Zhang et al., Nanhu Laboratory, March 7, 2026, Nature Aging, https://www.nature.com/articles/s43587-026-01087-1 ) - PEP, a normal glycolytic intermediate, is an endogenous cGAS inhibitor that declines with age, unleashing cGAS-STING-driven inflammaging. Restoring PEP before its natural age-related decline promotes healthy aging in mice and alleviates Alzheimer's disease symptoms. 5) Cellular Aging Signatures in the Plasma Proteome Record Human Health and Disease (Ding, Bot, Chen et al., Stanford University, February 12, 2026, bioRxiv, https://www.biorxiv.org/content/10.64898/2026.02.10.704909v1 ) - The largest plasma proteomics aging study ever: 60,000 individuals, 7,000+ proteins, biological age estimates for 40+ cell types. APOE4 carriers show older astrocytes but younger macrophages, directly linking cell-type-specific aging to Alzheimer's disease risk. Cellular aging signatures predict incident disease and mortality over 15 years of follow-up. This podcast is AI generated and may contain errors.

In this episode, we discuss five groundbreaking papers from longevitypapers.com on mechanisms of aging and potential interventions: 1) Enhanced non-enzymatic H2S generation via natural diallyl sulforated compounds extends lifespan and healthspan in mice (Cáliz-Molina et al., Cell Metabolism, December 2025, https://pubmed.ncbi.nlm.nih.gov/41421349/ ) - Diallyl sulforated compounds boost endogenous hydrogen sulfide, improving mitochondrial function, suppressing mTOR-related aging pathways, and restoring protein persulfidation in aged mice. This non-pharmacological approach addresses multiple hallmarks of aging. 2) Selective activation of NaV1.3 restores lymphatic contractility in aging and injury (Ruscic et al., Massachusetts General Hospital, December 2025, https://www.biorxiv.org/content/10.64898/2025.12.15.694318v1 ) - A newly identified voltage-gated sodium channel selectively expressed in lymphatic muscle can be pharmacologically activated to restore lymphatic pumping in aged mice, addressing a previously untargeted aging system critical for immunity and metabolic homeostasis. 3) Mitochondrial RNA cytosolic leakage drives the SASP (Victorelli et al., Mayo Clinic, December 2025, https://pubmed.ncbi.nlm.nih.gov/41392167/ ) - Beyond mtDNA, mitochondrial RNA leakage activates RIG-I and MDA5 sensors to drive senescence-associated inflammation. BAX/BAK deletion reduces SASP, suggesting RNA sensors as novel druggable targets. 4) Awakening intracellular immunity for functional HIV cure via CD4 T cell reprogramming (Lanna et al., University College London, January 2026, https://www.biorxiv.org/content/10.64898/2026.01.08.698387v1 ) - Transient CD4 T cell reprogramming activates antiviral telomere transfer programs that eliminate integrated HIV DNA, offering potential functional cure. Since HIV accelerates epigenetic aging by ~13 years, this is transformative for aging in HIV+ populations and may generalize to other age-related immune dysfunction. 5) Rapamycin exerts geroprotective effects by enhancing DNA damage resilience in human immune cells (Kell et al., University of Oxford, January 2026, https://pubmed.ncbi.nlm.nih.gov/41546123/ ) - First human mechanistic study of low-dose rapamycin shows direct genoprotection of aged T cells through reduced DNA lesional burden and p21 suppression. Off-patent, low-cost, and immediately clinically translatable. This podcast is AI generated and may contain errors.

A Fourfold Male-Specific Lifespan Extension via Canonical Insulin/IGF-1 Signaling (Russell et al., University of Alabama at Birmingham, December 5, 2025, BioRxiv, https://www.biorxiv.org/content/10.64898/2025.12.02.691904v1 ) - We explore how the daf-2 mutation extends male C. elegans lifespan by an extraordinary 4-fold with preserved healthspan, establishing sex as a primary determinant of longevity potential rather than a secondary variable. This challenges our understanding of insulin/IGF-1 signaling and suggests sex-specific interventions may be critical for anti-aging therapeutics. 2) Lifespan-extending downregulation of insulin signaling reduces germline mutation load (Duxbury et al., University of East Anglia, December 5, 2025, BioRxiv, https://www.biorxiv.org/content/10.64898/2025.12.05.692572v1 ) - We examine how reducing insulin/IGF-1 signaling in adulthood simultaneously extends somatic lifespan and reduces germline mutation rates by ~50 percent, dissolving the classical reproductive-somatic trade-off. The HRDE-1 epigenetic silencing pathway emerges as a novel mechanism linking nutrient sensing to genome stability across generations. 3) A Global Metabolomic and Lipidomic Landscape of Human Plasma Across the Lifespan (Liu et al., University of Science and Technology of China, December 6, 2025, Aging Cell, https://pubmed.ncbi.nlm.nih.gov/41351469/ ) - We discuss how untargeted metabolomics of 136 individuals reveals nonlinear metabolic trajectories with critical transition points, elevated amino acids and lipid dysbalance characterizing aging, and development of a clinically applicable plasma metabolite-based aging clock that may outperform epigenetic clocks for mortality prediction. 4) Genome-wide association study of proteomic aging reveals shared genetic architectures with longevity, early life development, and age-related diseases (Argentieri et al., Massachusetts General Hospital, December 4, 2025, MedRxiv, https://www.medrxiv.org/content/10.64898/2025.12.03.25341518v1 ) - We analyze 27 genetic loci associated with proteomic age gap showing strong genetic correlation with longevity (r=-0.83), with validated polygenic scores predicting increased odds of exceptional longevity and mechanistic links to FTO and m6A methylation-regulated metabolic aging. 5) Gut metabolism links precision nutrition, exercise, and healthspan in Drosophila melanogaster

In this episode, we analyze four standout papers from longevity research (November 17–30, 2025). The sources indicate that none achieve the paradigm-shifting breakthrough required for decades-long (10+ year) human lifespan extension. 1. Targeting Nuclear Tension to Rejuvenate Blood (Paper #74) Title: Targeting RhoA nuclear mechanoactivity rejuvenates aged hematopoietic stem cells Authors: Eva Mejía-Ramírez, Pablo Iáñez Picazo, Barbara Walter, et al. Source/Date: Nature Aging, November 25, 2025 URL: https://pubmed.ncbi.nlm.nih.gov/41286... This paper identifies a genuinely novel mechanotransduction axis (NE tension → P-cPLA2 → RhoA) in aging hematopoietic stem cells (HSCs). Aged HSCs accumulate pathological nuclear envelope (NE) tension, which hyperactivates RhoA signaling, leading to loss of youthful H3K9me2 heterochromatin and de-repression of retrotransposons. RhoA inhibition pharmacologically restores NE homeostasis, recovers H3K9me2, and improves HSC regenerative capacity and lymphomyeloid balance in vivo. This work is strong mechanistic discovery, but the effects are HSC-specific. Systemic longevity impact is limited, potentially leading to 2–4 year healthspan gains in immune resilience in highly optimized scenarios, falling short of transformative longevity goals. 2. AI Agents for Intervention Discovery (Paper #41) Title: Autonomous AI Agents Discover Aging Interventions from Millions of Molecular Profiles Authors: Ying, K., Tyshkovskiy, A., Moldakozhayev, A., et al. Source/Date: BioRxiv, November 20, 2025 URL: https://www.biorxiv.org/content/10.11... This research uses the ClockBase Agent to autonomously reanalyze 43,602 intervention-control comparisons across multiple aging clocks. It identified over 500 interventions that reduce biological age, including ouabain. Experimental validation showed ouabain reduced frailty, decreased neuroinflammation, and improved cardiac function in aged mice. This represents genuine methodological novelty in mining existing biomedical data for aging interventions, but the intervention (ouabain) is a known cardiac glycoside, and the effects are considered modest. 3. Splicing Dysregulation in Muscle Aging (Paper #22) Title: TGFβ-Smad3 signaling restores cell-autonomous Srsf1-mediated splicing of fibronectin in aged skeletal muscle stem cells Authors: Yuguo Liu, Svenja C Schüler, Simon Dumontier, et al. Source/Date: Nature Communications, November 22, 2025 URL: https://pubmed.ncbi.nlm.nih.gov/41271... This paper maps the TGFβ1-Smad3-Srsf1-EDB(+)FN pathway linking RNA splicing dysregulation to muscle regenerative failure in aging. TGFβ1 activation restored fibronectin splicing and improved muscle repair in aged mice during a defined regeneration interval. This is solid mechanistic work aligning with RNA splicing being an emerging core aging axis. However, the therapeutic window appears narrow, confined to acute regeneration intervals, and lacks whole-organism lifespan data. 4. The Nonhuman Primate Aging Atlas (Paper #70) Title: A multi-omics molecular landscape of 30 tissues in aging female rhesus macaques Authors: Gong-Hua Li, Xiang-Qing Zhu, Fu-Hui Xiao, et al. Source/Date: Nature Methods, November 18, 2025 URL: https://pubmed.ncbi.nlm.nih.gov/41249... This is the first comprehensive multi-omics atlas across 30 tissues in nonhuman primates. The key finding is that tissue aging is asynchronous and stratified by mRNA translation efficiency; tissues with declining translational capacity exhibit accelerated aging and drive whole-body aging. This paper links translational capacity to tissue-specific aging rates but is primarily descriptive, providing an excellent resource rather than interventional proof of lifespan extension. Overall Assessment: This body of work is valuable for resource building and hypothesis generation, focusing on incremental improvements across areas like mechanotransduction, translational capacity, and AI methodology. However, none provide the clear therapeutic path or f

In this episode of Longevity Papers, we critically analyze the five most impactful papers from this week (November 10-14, 2025) selected from longevitypapers.com for biotech researchers and longevity enthusiasts. 1) 'circHERC1-A telomerase activator' (Yumeng Cui et al., Beijing Institute of Biotechnology, November 12, 2025, Science Advances, https://pubmed.ncbi.nlm.nih.gov/41223261/ ) - We explore how the circular RNA circHERC1 activates telomerase expression by recruiting RNA Pol II to the TERT promoter. Notably, circHERC1 declines with age, correlating with reduced telomerase activity. Restoration via AAV or extracellular vesicles enhances telomere elongation and reverses aging phenotypes including improved cognition and physical performance. This addresses telomere attrition as a hallmark of aging, building on decades of telomerase biology since Greider/Blackburn 1985, with a unique endogenous regulatory mechanism distinct from previous failed small-molecule approaches. 2) 'HDAC2 inhibition restores H4K16 Acetylation and Rescues Cellular Senescence in Hutchinson-Gilford progeria syndrome' (Karimpour et al., University of Alberta, November 7, 2025, BioRxiv, https://www.biorxiv.org/content/10.1101/2025.11.07.687234v1 ) - We examine how systematic screening identified HDAC2 (not SIRT1) as the dominant deacetylase responsible for H4K16ac loss in accelerated aging. Pharmacological HDAC2 inhibition restores H4K16 acetylation, rescuing nuclear morphology, proliferative capacity, and reducing senescence in HGPS cells. This represents a specificity win over pan-HDAC inhibitors that failed clinically, with potential transformative implications if HGPS lifespan is extended, proving concept for broader aging populations. 3) 'Targeting Endothelial KDM5A to Attenuate Aging and Ameliorate Age-Associated Metabolic Abnormalities' (Rifeng Gao et al., Zhejiang University, November 14, 2025, Advanced Science, https://pubmed.ncbi.nlm.nih.gov/41236095/ ) - We discuss how endothelial-specific KDM5A deficiency causes shortened lifespan with senescent phenotypes (fat accumulation, reduced thermogenesis, kyphosis), demonstrating causative endothelial aging. The mechanism links epigenetics to metabolism: KDM5A regulates H3K4me3 at FABP4 promoters. Maintaining VEC-specific KDM5A prolongs lifespan, establishing the KDM5A/FABP4 axis as a therapeutic target for vascular aging and systemic metabolic dysfunction. 4) 'Mitochondrial dysfunction drives age-related degeneration of the thoracic aorta' (Arjune S Dhanekula et al., University of Washington, November 14, 2025, GeroScience, https://pubmed.ncbi.nlm.nih.gov/41233677/ ) - We analyze how elamipretide (SS-31), a mitochondria-targeted peptide in clinical trials, restores Complex II respiration to young levels in aged aortas, reducing stiffness, elastin breaks, and inflammatory MMP9 expression. This demonstrates causation via pharmacological rescue of a hallmark aging process, with SS-31 already being tested in Friedreich's ataxia and heart failure—this aging application would expand clinical relevance significantly. 5) 'Defining Microbiota-Derived Metabolite Butyrate as a Senomorphic: Therapeutic Potential in the Age-Related T Cell Senescence' (Nia Paddison Rees et al., University of Birmingham, November 7, 2025, Aging Cell, https://pubmed.ncbi.nlm.nih.gov/41201238/ ) - We examine butyrate as a senomorphic agent preventing senescence accumulation rather than eliminating it. The mechanism: butyrate suppresses IL-6/IL-8 SASP secretion via mTOR/NF-κB inhibition, with reduced DNA damage markers and mitochondrial ROS. Young fecal microbiota reverse aged splenic senescence in vivo, implicating the microbiota-immune axis. Butyrate is dietary, cheap (0/month), and represents a scalable intervention if lifespan studies confirm efficacy. This podcast is AI generated and may contain errors.